Evaluation of tumor markers (HER-2/neu oncoprotein, CEA, and CA 15.3) in patients with locoregional breast cancer: Prognostic value

Tumor Biology

Volumn 31, Issue 3, 2010, Pages 171-180

  Molina, Rafael ^a   Augé, Jose M ^a   Escudero, Jose M ^a   Filella, Xavier ^a   Zanon, Gabriel ^a   Pahisa, Jaume ^a   Farrus, Blanca ^a   Muñoz, Montserrat ^a   Velasco, Martin ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

Breast cancer; Disease free survival; Tumor markers

Indexed keywords

ANTINEOPLASTIC AGENT; CA 15-3 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; HORMONE; TUMOR ANTIGEN; TUMOR MARKER; MUCIN 1;

ADJUVANT THERAPY; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIMARY TUMOR; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; TUMOR VOLUME; BLOOD; BREAST TUMOR; MIDDLE AGED; MORTALITY;

BREAST NEOPLASMS; CARCINOEMBRYONIC ANTIGEN; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MIDDLE AGED; MUCIN-1; RECEPTOR, ERBB-2; TUMOR MARKERS, BIOLOGICAL;

EID: 77953255792     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-010-0025-9     Document Type: Article

References (49)

1. Parkin DM, Pisani P, Ferlay J. Estimates of the worldwide incidence of 25 major cancers in 1999. Int J Cancer. 1999;80:827-41.
2. Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E. Cancer statistics, 2004. CA Cancer J Clin. 2003;53:4-25.
3. Early Breast Cancer Trialist's Collaborative Group. Polychemotherapy for early breast cancer: an overview of the randomised clinical trials. Lancet. 1998;352:930-42.
4. Bieglmayer C, Szepesi T, Kopp B, Hoffmann G, Petrik W, Guettuoche K, et al. CA15.3, MCA, CAM26, CAM29 are members of a polymorphic family of mucin-like glycoproteins. Tumor Biol. 1991;12:138-48.
5. Price MR, Rye PD, Petrakou R, Murray A, et al. Summary report on the ISOBM TD-4 workshop: analysis of 56 monoclonal antibodies against the MUC1 mucin. Tumor Biol. 1998;19(1):1-20.
6. Dnistrian AM, Schwartz MK, Greenberg EJ, Smith CA, Schwartz DC. Evaluation of CAM26, CAM29, CA15.3 and CEA as circulating tumor markers in breast cancer patients. Tumor Biol. 1991;12:1282-90.
7. Heinze T, Schurenkamper P, Minguillon C, Lichtenegger W. Mammary serum antigen (MSA), Ca 549, CA 15-3 and CEA in breast cancer preoperative sensitivity and correlation to prognostic factors. Anticancer Res. 1997;17:2953-4.
8. Molina R, Jo J, Filella X, Zanon G, Pahisa J, Muñoz M, et al. CerbB- 2 oncoprotein in the sera and tissue of patients with breast cancer: utility in prognosis. Anticancer Res. 1996;16:2295-300.
9. Volas GH, Leitzel K, Teramoto Y, Grossberg H, Demers L, Lipton A. Serial serum c-erbB-2 levels in patients with breast carcinoma. Cancer. 1996;15(78):267-72.
10. Molina R, Barak V, van Dalen A, Duffy MJ, Einarsson R, Gion M, et al. Tumor markers in breast cancer. European Group on Tumor Markers Recommendations. Tumor Biol. 2005;26:281-93.
11. Lumachi F, Basso SM, Brandes AA, Pagano D, Ermani M. Relationship between tumor markers CEA and CA 15-3, TNM staging, estrogen receptor rate and MIB-1 index in patients with pT1-2 breast cancer. Anticancer Res. 2004;24:3221-4.
12. Canizares F, Sola J, Perez M, Tovar I, De Las HM, Salinas J, et al. Preoperative values of CA 15-3 and CEA as prognostic factors in breast cancer: a multivariate analysis. Tumour Biol. 2001;22:273-81.
13. Molina R, Filella X, Alicarte J, Zanon G, Pahisa J, Munoz M, et al. Prospective evaluation of CEA and CA 15.3 in patients with locoregional breast cancer. Anticancer Res. 2003;23:1035-41.
14. Gion M, Boracchi P, Dittadi R, Biganzoli E, Peloso L, Mione R, et al. Prognostic role of serum CA15.3 in 362 node-negative breast cancers. An old player for a new game. Eur J Cancer. 2002;38:1181-8.
15. Duffy MJ, Duggan C, Keane R, Hill AD, McDermott E, Crown J, et al. High preoperative CA 15-3 concentrations predict adverse outcome in node-negative and node-positive breast cancer: study of 600 patients with histologically confirmed breast cancer. Clin Chem. 2004;50:559-63.
16. Olayioye MA, Neve RM, Lane HA, Hynes NE. The erbB signalling network: receptor heterodimerization in development and cancer. EMBO J. 2000;19:3159-67.
17. Ross JS, Fletcher JA. HER-2/neu (C-erbB-2) gene and protein in breast cancer. Am J Clin Pathol. 1999;112:53-67.
18. Potter CR, van Doele S, van de Vijver MJ, Pauwells C, Maertens G, de Boever J, et al. The expression of the neu oncogene product in breast lesions and in normal fetal and adult human tissues. Histopathology. 1989;15:351-62.
19. Slamon D, Pegram M. Rationale for Trastuzumab (Herceptin) in adjuvant breast cancer trials. Sem Oncol. 2001;28:13-9.
20. Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol. 2007;25:5287-312.
21. Harries M, Smith I. The development and clinical use of Trastuzumab. Endocr Relat Canc. 2002;9:75-85.
22. Ross JS, Fletcher JA, Linette GP, Stec J, Clark E, Ayers M, et al. The HER-2/neu gene and protein in breast cancer 2003; biomarker and target of therapy. Oncologist. 2003;8:307-25.
23. Molina R, Jo J, Filella X, Bruix J, Castells A, Hague M, et al. Serum levels of C-erbB-2 (HER-2/neu) in patients with malignant and non-malignant diseases. Tumor Biol. 1997;18:188-96.
24. Schwarz MK, Smith C, Schwartz DC, Dnistrian A, Neiman I. Monitoring therapy by serum HER-2/neu. Int J Biol Markers. 2000;15:324-9.
25. Wu JT, AstgillME, Zhang P. Detection of the extracellular domain of c-erbB-2 oncoprotein in sera from patients with various carcinomas: correlation with tumor markers. J Clin Lab Anal. 1993;7:31-40.
26. Cook GB, Neamann IB, Goldblatt JL, Cambetas DR, Hussain M, Luftner D, et al. Clinical utility of serum HER-2/neu testing on the Bayer Immuno 1 automated system in breast cancer. Anticancer Res. 2001;21:1465-70.
27. Carney WP, Neumann R, Lipton A, Leitzel K, Ali S, Price CP. Monitoring the circulating levels of the HER-2/neu oncoprotein in Breast cancer. Clin Breast Cancer. 2004;5:105-16.
28. Carney WP. The emerging role of monitoring serum HER-2/neu oncoprotein levels in women with metastatic breast cancer. Lab Med. 2003;34:58-64.
29. Fehm T, Gebauer G, Jager W. Clinical utility of serial serum cerB- 2 determinations in the follow-up of breast cancer patients. Breast Cancer Res Treat. 2002;75:97-106.
30. Molina R, Filella X, Zanon G, Pahisa J, Alicarte J, Muñoz M, et al. Prospective evaluation of tumor markers (c-erbB-2 oncoprotein, CEA and CA 15.3) in patients with loco-regional breast cancer. Anticancer Res. 2003;23:1043-50.
31. Dittadi R, Zancan M, Perasole A, Gion M. Evaluation of HER-2/ neu in serum and tissue of primary and metastatic breast cancerpatients using an automated enzyme immunoassay. Int J Biol Markers. 2001;16:255-61.
32. Luftner D, Schnabel S, Possinger K. c-erbB-2 in serum of patients receiving fractionated paclitaxel chemotherapy. Int J Biol Markers. 1999;14:55-9.
33. Schippinger W, Regitnit P, Bauernhofer T, et al. The course of serum HER-2/neu levels as an independent prognostic factor for survival in metastatic breast cancer. Oncol Rep. 2004;11:1331-6.
34. Molina R, Jo J, Zanon G, Filella X, Farrus B, Muñoz M, et al. Utility of C-erbB-2 in tissue and in serum in the early diagnosis of recurrence in breast cancer patients: comparison with carcinoembryonic antigen and CA15.3. Br J Cancer. 1996;74:1126-31.
35. Kostler WJ, Schwab B, Singer C, et al. Monitoring of serum HER-2/neu predicts response and progression-free survival to trastuzumab-based treatment in patients with metastatic breast cancer. Clin Cancer Res. 2004;10:1618-24.
36. Early Breast Cancer Trialist's Collaborative Group. Tamoxifen for early breast cancer: an overview of randomized trials. Lancet. 1998;351:1451-67.
37. Mirza AN, Mirza NQ, Vlastos G, Singletary E. Prognostic factors in node-negative breast cancer. A review of studies with sample size more than 200 and follow-up more than 5 years. Ann Surg. 2002;235:10-26.
38. Yamauchi H, Stearns V, Hayes DF. When is a tumor marker ready for prime time? A case study of c-erbB-2 as a predictive factor in breast cancer. J Clin Oncol. 2001;19:2334-56.
39. Piccart MJ, Di Leo A, Hamilton A. HER2: a predictive factor ready to use in the daily management of breast cancer patients? Eur J Cancer. 2000;36:1755-61.
40. Fehm T, Maimonis P, Weitz S, Teramoto Y, Katalinic A, Jager W. Influence of circulating c-erbB-2 serum protein on response to adjuvant chemotherapy in node-positive breast cancer patients. Br Cancer Res Treat. 1997;43:87-95.
41. Fontana X, Ferrari P, Namer M, Peysson R, Salamon C, Bussiere C. C-erbB2 gene amplification and serum level of c-erb-B2 oncoprotein at primary breast cancer diagnosis. Anticancer Res. 1994;14:2099-104.
42. Park BW, Oh JW, Kim JH, Park SH, Kim KS, Kim JH, et al. Preoperative CA 15.3 and CEA serum levels for breast cancer outcome. Ann Oncol. 2008;19:675-81.
43. Sturgeon CM, Duffy MJ, Stenman UH, Lilja H, Brunner N, Chan DW, et al. National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clin Chem. 2008;54:11-79.
44. O' Hanlon DM, Kerin MJ, Koent P, Maher D, Grimes H, Given HF. An evaluation of preoperative CA15.3 measurement in primary breast carcinoma. Br J Cancer. 1995;71:1288-91.
45. Molina R, Jo J, Filella X, et al. C-erbB-2 oncoprotein, CEA and CA 15.3 in patients with breast cancer: prognostic value. Br Cancer Res Treat. 1998;51:109-19.
46. Sugano K, Ushiama M, Fukutomi T, Tsuda H, Kitoh T, Ohkura H. Combined measurement of the cérbB-2 protein in breast carcinoma tissues and sera is useful as a sensitive tumor marker for monitoring tumor relapse. Int J Cancer. 2000;89:329-36.
47. Esteva FJ, Cheli CD, Fritsche H, Fornier M, Slamon D, Thiel RP, et al. Clinical utility of serum HER/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies. Breast Cancer Res. 2005;7:436-43.
48. Ebeling FC, Schmitt UM, Untch M, et al. Tumor markers CEA and CA 15.3 as prognostic factors in breast cancer. Univariate and multivariate analysis. Anticancer Res. 1999;19:2545-50.
49. McLauglin R, McGrath J, Grimes H, Given HF. The prognostic value of the tumor marker CA 15.3 at initial diagnosis of patients with breast cancer. Int J Biol Markers. 2000;15:340-2.